Metrics Reinforce that Clinically Guided Cannabinoid Care Contributes to Meaningful Symptom Improvement via Broadly Accepted PROMIS and PIO (Personally Important Outcome) Measures.
Latest Results are Focused on Older Adults and those in Cancer Treatment
EO Care, Inc., the leader in cannabinoid-based symptom management, released data using PROMIS* measures showing that patients leveraging its guided cannabinoid products and care platform reported meaningful improvements for pain, sleep, anxiety, and nausea/vomiting**.
Meaningful improvements were reported by patients after one (1) week and sustained through four (4) weeks of guided cannabinoid care, particularly among people over 50 and cancer patients. Patients also reported low rates of use-limiting side effects with further reductions after receiving updated recommended product and/or dosing guidance via EO Care’s digital care platform.
Key findings for patients over 50 include:
- 55% of patients reported meaningful improvement in pain interference after one week, improving to 74% after four weeks
- 73% of patients reported meaningful improvement in sleep disturbance after one week, improving to 81% after four weeks
- 73% of patients reported meaningful improvement in anxiety after one week, improving to 77% after four weeks
- 58% of patients reported meaningful improvement in gastrointestinal nausea and vomiting after one week
Key findings for cancer patients include:
- Cancer patients saw meaningful improvements across pain (69%), sleep disturbance (77%), anxiety (77%), and nausea/vomiting (92%) after four weeks of care
- ER visits and unplanned hospitalizations due to symptoms were significantly lower than typically seen in cancer populations through the first month of use
Additionally, key findings from Personally Important Outcomes (PIOs), which are outcomes that a patient identified as meaningful such as walking, cooking, exercise, or playing with their grandkids, include:
- 57% of people saw a clinically meaningful improvement in PIOs (>=2 pt reduction in difficulty scale)
- Respondents’ PIOs improved by 30% on average
“There’s a paucity of data on the effectiveness of cannabinoid care for symptom management. The power of our care platform allows us to close that gap,” said Sean Collins, CEO and co-founder of EO Care. “Millions of people, particularly the elderly and cancer patients, are turning to cannabinoid care for symptom relief, and they should have trusted, evidence-based solutions to guide their care. Our real-world data and insights provide an important window into the value of a scalable care platform that helps people find the right cannabinoid products and dosage, guided by clinical expertise.”
This data follows a 2024 cost of care analysis by the Milliman Report and commissioned by EO Care which can be found here.
These results reinforce EO Care’s commitment to providing personalized, clinically responsible cannabinoid guidance to patients. EO Care follows all HIPAA regulations. The company does not sell patient data, and only authorized clinicians and care team members can access patient records.
*PROMIS (Patient-Reported Outcomes Measurement Information System) is an NIH-developed tool for assessing physical, mental, and social health.
**Meaningful improvement is defined as a 3-point or greater reduction in the patient’s PROMIS score.
About EO Care, Inc.
EO is the leader in cannabinoid-based symptom management. The company provides personalized, clinically responsible care through its unique, scalable digital care platform and affordable, medicalized cannabinoid products. Board members, advisors and investors include Regina Benjamin, MD, MBA, former Surgeon General of the United States; Kristi Savacool, former CEO of AON Hewitt; and Bill Van Faasen, former CEO of Blue Cross Blue Shield Massachusetts. For more information, visit eo.care.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112755135/en/
Contacts
Media Contact: EO Care Media Relations press@eo.care